Developer of a cell coding technology designed for a new generation of cell therapies by democratizing access to consist
Developer of a cell coding technology designed for a new generation of cell therapies by democratizing access to consistent and functional human cells.
Biotechnology📍 Cambridge, United KingdomFounded 2016
Current Valuation
$739.42M
as of 2021-Q4
PRIVATE
QL Price
$739.42M
0% vs last round
QuantLogix's current estimate for bit.bio, published 2026-09-27 — in line with the last disclosed round of $739.42M (2021-Q4).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$739.42M
2021-Q4
weight 0.04
How this price has held up
No round has priced for bit.bio since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, bit.bio, 2026-09-27 (e3bb1c64e5accd20).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is bit.bio going public?
No. bit.bio is private and has not filed to go public. There is no S-1 on file.
What is bit.bio's valuation in 2026?
bit.bio is valued at $739.42M as of 2021-Q4, set by its Series B ($187.51M, Dec 2021). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has bit.bio filed an S-1?
No public S-1 is on file for bit.bio.
How much has bit.bio raised?
bit.bio has raised $250.32M in total, most recently a Series B of $187.51M in Dec 2021.
Is bit.bio publicly traded — can you buy bit.bio stock?
No. bit.bio is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for bit.bio on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2016
HQ
Cambridge, United Kingdom
Employees
164
Total Raised
$250.32M
Last Round
Series B — $187.51M (Dec 2021)
IPO Status
private
Fundraising Status
Series B · $187.51M · 4y 9mo ago
privateTotal raised $250.32M
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series B
$187.51M
Dec 2021
—
$739.42M
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for bit.bio — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-19. Re-checked weekly.
Talent Signal
Hiring trend
▶ Hiring steady
-6% vs 2026-08
Open roles
17
via careers page
Product-build share
18%
engineering, research, product, design
Trajectory
strengthening
go-to-market push — Only 18% of open roles build product — hiring is concentrated in sales/marketing/ops (11 of 17 open roles are support).
Recent senior hire: 1 senior hire (CEO).
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Key Executive Moves
INDr Emma PepperellCEO · 2026-08-23
From trusted-source news extraction (deep-enrich pipeline); dates approximate publication, not effective date.
Private Medical Insurance, with discounts on gym memberships, restaurants and otMedical Insurance including Dental and VisionResearch Product UpdatesSkip to main contentOrder supportStandard terms & conditions for sales and services
Counted from bit.bio's live job board as of 2026-09-16; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Health CareBiotechnologyCommercial
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2021-Q4. Refreshed quarterly.